Brigham Young University

BYU ScholarsArchive
Theses and Dissertations
1975-12-01

Studies of N⁵,
N , N¹⁰-methylene
N¹ -methylene tetrahydrofolate reductase from
porcine kidney and mouse L1210-induced tumor tissues,
purification and interaction with antifolates
David W. Jayme
Brigham Young University - Provo

Follow this and additional works at: https://scholarsarchive.byu.edu/etd

BYU ScholarsArchive Citation
Jayme, David W., "Studies of N⁵, N¹⁰-methylene tetrahydrofolate reductase from porcine kidney and
mouse L1210-induced tumor tissues, purification and interaction with antifolates" (1975). Theses and
Dissertations. 8241.
https://scholarsarchive.byu.edu/etd/8241

This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion
in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please
contact ellen_amatangelo@byu.edu.

(Qp

f-02..
. J3~

t·</7(;

STUDIES OF NS,NlO_METHYLENE TETRAHYDROFOLATE REDUCTASE FROM
PORCINE KIDNEY AND MOUSE Ll210-INDUCED TUMOR TISSUES:
PURIFICATION AND INTERACTION WITH ANTIFOLA'l'ES

A Thesis
l?resented to the
Graduate Section of Biochemistry
Brigham Young University

In Partial Fulfillment
of the Requirements for the Degree
Master of science

by

David

w.

Jayme

December .1975

This thesis, by David

w.

Jayme, is accepted in its present form

by the Graduate section of Biochemistry, Department of Chemistry of
Brigham Young University as satisfying the thesis requirement for the
degree of Master of Science.

Typed by:

Elizabeth Sykora Prisbrey

ii

TABLE OF CONTENTS
LIST OF FIGURES •
LIST OF TABLES

•

•

•

•

lio

•

•

Ill

•

•

iv

•

vi

. . . . ..

ACKNOWLEDGMENTS • .
INTRODUCTION
ENZYME PURIFICATION •
Historical Aspects

Materials and Methods •

. ..

..

.. . . . .

..... ..... .. ...
.. .. . .
.. ...
•

•

•

·Ii

Iii

•

•

•

..,

•

ti

II

•

e

'

Purification of Methylene Tetrahydrofolate Reductase
Results and Discussion
ENZYME CHARACTERIZATION •
Kinetic Properties

•

•

•

••

•

•

•

•

•

•

..

•

•

ti

•

•

•

•

•

•

•

•

It

•

..

•

. ..
. . . .. .

..

•

. ... . "
•

• •

•

•

•

•

-

. . .. ..
'

•

5
5
Synthesis of N -Alkyl TetrahydrOfolate and N •Alkyl
Tetrahydrohornofolate Derivatives • • • • • • • •

12
15

24

• •

•

12

19

• • •

•

l

• • •

• • • •

• • • • • • • •

Inhibition Studies
overview

•

.

vii

..

~

•

~

lit

•

31
31
35

35
36

5

Inhibition of Kidney Reductase by N •Alkyl
Tetrahydrofolate Derivatives • • • • • • • • •

~

• • •

38

Reductase Inhibition by Alkylating Agents

• • • •

38

Reductase Inhibition by Folate Analogs
SUMMARY
LIST OF REFERENCES

..

... . . . . . . . . . . .
. . ... .
. ... .
iii

41
46

47

~

LIST OF FIGURES

..

1.

The Structure of Folate and Its Reduced Forms • • • • •

2.

Tetrahydrofolate-Mediated Transfer Reactions Involving
One-Carbon Groups • • • • • • • • • • • • • • • • • •

5

3.

The Structure of the Two Classical Antifolates,
Aminopterin and Methotrexate • • • • • • • • • • • • • •

9

4.

Schematic Diagram of the Reactions Catalyzed by
'l'hymidylate Synthetase--Dihydrofolate Reductase

4

• • •

10

10
The 5Reduction of Ns,N -methylene Tetrahydrofolate to
~ -methyl Tetrahydrofolate Catalyzed by Methylene
Tetrahydrofolate Reductase • • • • • • • • • • • • • • •

14

6.

Reaction Utilized for the Assay of Methylene
Tetrahydrofolate Reductase • • • • • • • • • • • • • • •

18

7.

Flowchart of the Purification of Methylene
Tetrahydrofolate Reductase • • • • • • • • • • • • • • •

23

a.

Elution Profile of Methylene Tetrahydrofolate
Reductase from DEAE-Sephadex Column •

........• .

2S

9.

Saturation of Kidney Methylene Tetrahydrofolate
Reductase by NS-methyl Tetrahydrofolate • • •

10.

saturation of Twnor Methylene Tetrahydrofolate
Reductase by NS-methyl Tetrahydrofolate
•

5.

11.

.•

32

. ..• • ..•

33

.

• •

Comparison of pH Optima for Purified Preparations
.. of Methylene Tetrahydrofolate Reductase from
·Kidney and Tumor Tissue
•

•

..

34

12.

Typical Spectrophotometric Scan of Isolated NS-alkyl
Tetrahydrofolate
• • • • • • • • • • . • • • • • • •

37

13.

Typical Lineweaver-Burk ~lot Illustrating
Competitive Inhibition of Methylene Tetrahydrofolate
Reductase Activity by NS-alkyl Tetrahydrofolate

...... ..

•

Derivatives . . . . . . . . . . . . . . . . . . . . .

iv

40

14.

Typical Lineweaver-Burk Plot Illustrating
Non-Competitive Inhibition of Methylene
Tetrahydrofolate Reductase Activity by
Folate Analogs • • • • • •

..

15.

..

Dixon Plot for the Determination of Ki Values

v

...
• • • • • •

44
45

LIST OF TABLES
I.
II.

III.

IV.

Purification of Methylene Tetrahydrofolate
Reductase from Porcine Kidney • • • • • •
Purification of Methylene Tetrahydrofolate
R~ductase from Mouse Ll210-Induced
Tumor Tissue • • • • • • • • • • • • • •

.....

.

26

. .... .

27

Inhibition of Kidney Methylene Tetrahydrofolate
Reductase by NS-alkyl Tetrahydrofolate and
NS-alkyl Tetrahydrohomofolate Derivatives • • • •

•

•

39

Ki Values of Selected lnhibitors of Methylene
Tetrahydrofolate Reductase • • • • • • • • • • • • •

43

vi

ACKNOWLEDGMENTS
I wish to express my appreciation to Dr. N. Appaji Rao, who
served as my research advisor, for his helpful suggestions and patient
encouragement throughout my thesis research.

Thanks is also rendered

to Dr. John H. Mangum who, in addition to providing the financial
support for

my

project, helped me to develop a sense of pride in my

accomplishments, and to Or. Albert D. Swensen who has set an example
for me through his concern for students which I hope to emulate.
Dr. August

w.

To

Jaussi I wish to express my appreciation for not havin9

discouraged my constant tide of unanswerable questions; and to the
Chemistry Department Faculty of Brigham Young University, in particular
to Ors. Fred G. White and Marvin A. Smith, who far surpassed the
mundane requirements of rote memorization by teaching their students
to think.

In addition, my expression of gratitude would be incomplete

without acknowledging the incalculable assistance of Dr. P. M. Harish
Kumar and KIXX radio for helping me to stay awake during the long,
late hours in the laboratory.
It is to my wife, Donna, who, through her loving support and
abiding faith, has helped me to maintain a balance in my life and
caused me to bless the day we married, and to my little daughter, Lara,
who greeted me at the door with the same happy smile, even when my
column had run dry, that I desire to dedicate this thesis as a small

vii

expression of recognition for all they have dedicated to me.

Appre-

ciation is heartfelt for my parents, who instilled in me a desire
to seek truth, wherever it might be found, and for my parents-in-law,
who have been a source of strength and encouragement throughout my
graduate work.

Finally, I wish to express my eternal gratitude to my

Heavenly Father, for having blessed me with the talents I would need
to achieve those things of lasting worth and for allowing me to
prepare myself so as to be of greater service to Him.

viii

INTRODUCTION
Cancer Chemotherapy
"Cancer is one of the oldest diseases affecting mankind, and
the efforts at treatment have been recorded as lonq aqo as the use of
arsenic pastes in ancient Egypt.

Today, cancer is second only to

cardiovascular disease as the major cause of death in the United State&
Each year an estimated 650,000 new cases are diagnosed and over one
million known patients continue treatment.

The major difficulties in

mounting a rapid scientific assault on cancer are that it encompasses
more than 100 clinically distinct diseases and is inextricably linked
to fundamental life processes that still are not completely
understood "(l).
In the attempt to "cure" cancer, i.e. provide a normal life
expectancy for the treated cancer patient, clinical treatment has
evolved to the single or combined utilization of three modalities a
surgery, radiotherapy, and chemotherapy.

While the prognosis for a

panacea is neither imminent nor, perhaps, feasible, recent scientific
advances both in the early diagnosis of malignancy and its subsequent
treatment have fostered a "humble optimism•• among clinicians and
researchers.
While surgical therapy may well be the only means by which
certain neoplastic diseases may be cured, many patients as a result

1

2

of prolonged incubation prior to diagnosis have surpassed the range of
surgical care.

A prominent investigator in cancer chemotherapy

recently stated, using the carcinoma of the colon as an example, that
"over 10 percent ••• are unresectable at the time of operation, and an
additional 25 percent have visible metastases which cannot be
resected"(2).

He further suggested factors in addition to the extent

of metastatic involvement of the disease which limit surgical ap•
proaches, such as the general condition of the patient, interference
with vital organ function, and cosmetic considerations.

Nevertheless,

while surgery may not provide a cure in cases where the malignancy has
been disseminated, the removal of large tumor masses and other surgical
procedures have been demonstrated to increase the effectiveness of
supplementary radiotherapy and chemotherapy.
Although radiotherapy is the preferential modality for the cure
of certain radiosensitive malignancies, its general role is in palliative therapy and as an adjuvant to surgery or chemotherapy.

Adjuvant

radiotherapy has been demonstrated to facilitate the surgical removal
of certain tumors by initiating a reduction in tumor size prior to
surgery.

Palliative radiotherapy has been successfully combined with

systemic chemotherapy in the cure of patients with childhood solid
tumors.

As with surgery, radiotherapy is able to cure only with early

detection and diagnosis:

once the malignancy has spread to other

parts of the body, such localized modes of therapy, while able to
eradicate the primary locus of neoplasia, cannot control metastasis.
The objectives of cancer chemotherapy are two-fold: initially,
to produce a complete remission, i.e. to eliminate all clinical

3

evidence of the disease1 and secondly, to maintain remission as long
as possible.

Bodey and Frei (2) estimate that remission induction

therapy should produce about a 90-99% reduction in malignant cells, a
goal which has been achieved in several types of neoplastic diseases,
both localized and systemic.
Chemotherapeutic agents vary widely with regard to their source,
mode of action, effectiveness and toxicity, and consequently must be
subjected to a variety of screening processes prior to their use in
clinical practice.

Essentially, the diversity of antitumor agents may

be classified into five major categories: alkylating agents, antimetabolites, plant alkaloids, antibiotics, and endocrine agents.

Much

could be said concerning each of these categories of drugs and their
mechanism of action and major toxicity, but such an analysis exceeds
the scope of this work.

Rather, it is more pertinent to this discuss-

ion to focus on the area of antimetabolites, in particular those compounds, natural and synthetic, which are antagonistic to enzymes involved in folate metabolism.
Folic acid (pteroylglutamic acid) has been demonstrated to
function principally in the transfer of one carbon units of varying
levels of oxidation, primarily as derivatives of tetrahydrofolate.
known folate-dependent interconversions of one-carbon units are summarized in Figure 2.
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The two major reactions involved in the interconversion of these
tetrahydrofolate derivatives to levels of higher or lower oxidation
are catalyzed by two important branch-point enzymes:

5

N ,N

10

-methylene

5 10
tetrahydrofolate reductase and N ,N -methylene tetrahydrofolate

dehydrogenase.

N5 ,N10-methylene FH

+ NADPH +

4

+ NAD~ Dehydrogenas! N 5 ,N 10 -~ethenyl

J.f>

Depending on the oxidation level of the folate coenzyme, the

ra

4

tetrahydro~

folate derivative may then be utilized to donate one-carbon units into
three known biosynthetic pathways in mammalian systemst
l.

5

N -methyl FH may serve as the source of the methyl group
4
which is added to homocysteine to form methionine in the vitamin

s 12-dependent methionine synthetase reaction. Methionine is

lat~r

7

s-adenosylated for methylation reactions involving the formation of a
number of biogenic amines.
2.

5 10
N ,N -methylene FH

4

may be utilized directly as the source

of methyl groups in several reactions of pyrimidine nucleotide biosyn•
thesis, in particular, the thymidylate synthetase reaction which involves the folate dependent methylation of deoxyuridylate to yield
thymidylate.
5 10
N ,N -methylene FH

3.

4

+ dUMP

~

dTMP + FH

2

Two transformylase reactions have been shown to be in•

volved in purine ring biosynthesis, in each case catalyzing the donation of one-carbon units at the formyl level.
5

glycinamide ribotide + N ,N
ribotide + FH

10

-methenyl FH

4

t

formylglycinamide

4

5-amino-4-imidazolecarboxamideribotide + 10-formyl FH ;t
4
5-Formamido-4-imidazole carboxamide ribotide + FH

4

Particularly as a result of their direct participation in nucleotide
biosynthesis, the reactions involved in folate metabolism have long
been investigated by cancer researchers.
straightforward:

The rationale is simple and

cancer may be characterized by apparently unregu-

lated mitotic activity and cellular proliferation, which would require
a continuous, elevated rate of production of genetic material.

Inhib•

ition of the synthesis of nucleic acid precursors would thus reduce
the rate of cellular proliferation.

8

It was suggested by Friedkin (3) that inhibition of thymidylate
synthetase by an antimetabolite would produce a form of
death" of neoplastic tissue.

11

thymine•less

It was later discovered that a more ef•

ficient enzyme block of thymidylate synthesis could be applied to dihydrofolate reductase (4).

Substrate analogs such as 5-fluorouracil,

6-mercaptopurine and 6-thioguanine showed some promise in the direct
inhibition of thymidylate synthetase.

However, aminopterin and its

methylated derivative, methotrexate, which are stoichiometric inhibi•
tors of the dihydrofolate reductase reaction (see Figure 4), were more
effective.

While the action of such antifolate drugs was non-specific,

in that it affected both normal and tumor cells, the therapy was
quantitatively effective in checking the rapid proliferation of the
malignant cells.
While antifolates, such as methotrexate and aminopterint

have

been effective in cancer chemotherapy, particularly in the maintenance
of remission with minimal toxicity once complete remission has been
induced by vincristin or prednisone administration, it has become
apparent that the dihydrofolate reductase block exhibits some weakness•
es.

Although the inhibitor constant for methotrexate combination with

dihydrofolate reductase is in the range of 10-a to 10-9M, which con•
stitutes stoichiometric inhibition, there has been. evidence upon

prolonged drug administration of the induction of an enhanced dihydro•
£olate

reductase level.
Consequently, investigators began to consider other folate•

dependent enzymes as targets for chemotherapeutic drugs, but initially
the outlook was dismal.

While several enzymes in key positions in the

9
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ll
biosynthesis of DNA precursors could be inhibited by antifolate compounds, in order to achieve the required circulating inhibitor concen•
tration to reduce enzyme activity, the patient would have to receive
lethal dosages of the chemotherapeutic agent.

However, a recent

clinical publication (5) describing a combination therapy successful
in the treatment of osteogenic sarcoma which required the administra•
tion of near lethal doses of methotrexate, followed by rescue

~ith

citrovorum factor (5-formyl tetrahydrofolate) reported circulating
inhibitor levels in the range of 10

-3

to 10

-4

M.

This discovery gener-

ated considerable enthusiasm in our laboratory, as such relatively high
levels of antifolates have been demonstrated to inhibit a number of
folate-dependent enzymes.

ln response to a contract assigned to

Dr. John H. Mangum by the National Cancer Institute of the National
Institutes of Health, we are attempting the purification of five key
enzymes involved in folate metabolism.
with the purification of N ,N

5

10

My project has been concerned

~methylene tetrahydrofolate reductase

from porcine kidney and from mouse Ll210-induced solid tumor tissue.
My objective has been to purify the enzyme from each tissue to a
sufficient extent as to be free of other folate-dependent enzyme
contaminants, and to compare the "normal 11 enzyme with the "tumol'"
enzyme, with a particular emphasis on its kinetic properties and
inhibition by potential chemotherapeutic drugs.

ENZYME PURIFICATION
Historical Aspects
Methylene tetrahydrofolate reductase activity was first repor•
ted in 1959 by Donaldson and Keresztesy, when they observed that in•
cubation of a hot aqueous extract of horse liver with livet homogenates
resulted in a very significant increase in citrovorum factor
activity (6,7).

It was then postulated and later verified (8) that

5
prefolic A, in crude form, was converted to N -formyl tetrahydrofolate
(citrovorum factor) by two separate enzymatic reactions.

'l'he first

reaction converted prefolic A to tetrahydrofolate in the presence of a
suitable electron acceptor by the action of a flavin adenine
tide-linked enzyme system.

dinucleo~

Then, in the presence of a transformylatin9

enzyme and suitable substrate (e.g. formyl-L-glutamate), tetrahydro•
5
folate is formylated to N -formyl tetrahydrofolate.

When it was

observed (9) that formaldehyde was released in the oxidation of
prefolic A to tetrahydrofolate• Buchanan (10) suggested that prefolic
A and the newly discovered intermediate of methionine biosynthesis (11)
might be the same compound.

Donaldson and Keresztesy subsequently

reported (8) that the artificial oxidation of prefolic A by an electronaccepting dye involved the enzyme-catalyzed formation of an
~

5 10
N ,N -methylene bridge compound which then hydrolyzed to yield tetra-

hydrofolic acid and formaldehyde.

In addition, they presented evidence

12

13
for the physiological forward reaction of this FAD-dependent enzyme
which catalyzed the synthesis of prefolic A from tetrahydrofolate and
formaldehyde (or methanol) in the presence of flavin adenine dinucleo

4

tide and reduced diphosphopyridine nucleotide.
Although there were several studies of methylene tetrahydrofolate reductase activity, using relatively crude bacterial and liver
preparations (8 1 12-14), Katzen and Buchanan (15) succeeded in purifying the enzyme from an auxotrophic mutant of Escherichia coli (113-3).

a12-

By incubating this strain of bacterium in methionine and vitamin

deficient medium, a derepressed condition favoring a high methylene•
tetrahydrofolate reductase activity, Katzen and Buchanan were able to
cultivate bacterial cells with a 20-fold increase in specific activity
over repressed controls.

Following disruption of the cells, DNAase

treatment and centrifugation, the crude extract was subjected to

pro~

tamine sulfate fractionation and ammonium sulfate fractionation,
followed by column chromatography on DEAE-cellulose, which resulted in
an enzyme preparation which was purified 104-fold above the derepressed
crude extract.
Methylene tetrahydrofolate reductase has been isolated and
partially purified from several mammalian tissues, including equine
liver (8), porcine liver (16,17), rat liver (16), and bovine brain (18).
Of particular value, both in the suggestion of a general purification
format, which we have modified, and the availability of significant
kinetic data useful for comparison, was the paper of Kutzbach and
Stokstad (16).

14
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Materials and Methods
The chemicals used in this study were obtained from the follow•
ing sourcesa

FAO, NADPH, and folic acid - Sigma Chemical co.;

Cc 14 J•

formaldehyde - New England Nuclear Corp.; Menadione - Calbiochemt
Dimedon - J. T. Baker Chemical Co.

Other reagents were commercial

products of analytical grade.
DE-52, a preswollen, microgranular diethylaminoethyl(DEAE)cellulose preparation obtained from Whatman Biochemicals, Ltd. and
DEAE-sephadex A-50 from Pharmacia Fine Chemicals, Inc. were used for
column chromatographic separations.
Tetrahydrofolate was prepared by the catalytic hydrogenation
of folate according to the method of O'Dell
by Hatefi

~al.

(20).

the reverse direction, [c

P.t al. (19) as modified

The radioactive substrate for the assay in
14

5
J-N -methyl tetrahydrofolate, was prepared

according to the method of Blair and Saunders (21) as adapted from
Keresztesy and Donaldson (22).

One millicurie of [c

14

J-formaldehyde

was diluted with cold formaldehyde and combined with tetrahydrofolate
in the reaction vessel in an approximate molar ratio of 1:1.
reaction mixture was flushed

~ith

The

nitrogen prior to the addition of

the tetrahydrofolate and nitrogen was bubbled continuously throughout
the course of reaction to prevent air oxidation.

~he

condensation

5 10
product, the N ,N -methylene bridge compound, was then reduced with
5
potassium borohydride (200mg KBH /100mg FH ) to N -methyl tetrahydro4
4
folate, in which the methyl group bears the radioactive label.
reaction mixture was then loaded onto a DEAE•cellulose column

The

16

(3cm x lOcm) which had been washed and equilibrated with l liter of
0.133 M ammonium acetate in 0.01 M mercaptoethanol.
tetrahydrofolate was separated from unreacted

~he

s

N -methyl

tetr~hydrof olate

and

other folate contaminants by elution from a linear gradient generated

by 400mleach of 0.133 Mand 0.400 M anunonium acetate in 0.01 M
mercaptoethanol.

The purity of the product was determined by scanning

the UV spectra using a Cary 118 spectrophotometer (A
Amin~

max

= 290

run and

245 nm), and the combined fractions were lyophilized to remove

the volatile salt and concentrate the product.

The lyophilized

material was resuspended in water and stored at -40°C.
Protein concentration was determined by the Biuret method (23)
in the early steps of purification.

Column fractions were monitored

by measuring absorbance at 280 nm in a

~eckman

DU Spectrophotometer.

The Folin method according to LOwry, et al. (24) as modified by
!toss and Schatz (25) was used to determine the concentration of protein
at the final step of purification.
During purification, methylene tetrahydrofolate reductase was
routinely assayed in the reverse direction using menadione as the
electron acceptor and [C
strate (B,16).

14

5
)-N methyl tetrahydrofolate as the sub•

With the highly purified enzyme, a.spectrophotometric

assay in the forward direction as well as a quantitization of the
menadione reductase activity of the enzyme have been successfully
employed (16) and reported to coincide

~ith

the artificial assay

method used in this study.
The reaction volume for the incubation was

o.5

ml; containing

100 µmoles of ascrobate, 0.5 µmoles of FAD, approximately 350 runoles
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of menadione (added after preincubation), 250 nmoles of [C

14

s

1-N -methyl

tetrahydrofolate (2000 cpm/nrnole), and an aliquot of enzyme solution.
The mixture was pre-incubated at 37°C for five minutes and menadione
(O.l ml of a saturated solution in water at room temperature) was
added with mild agitation to start the reaction.

Assay tubes were in-

cubated at 37°C for 20 minutes and the reaction halted by the addition
of 0.3 ml dimedon reagent [3 mg/ml dimedon in l M acetate buffer
(pH 4.5)) with mixing and by heating the tubes in a boiling water bath
for five minutes to denature the enzyme.

After cooling the assay tubes

in ice, the isotopically labeled formaldehyde-dimedon condensation
product was extracted into 3 ml of toluene by vigorous agitation using
a Vortex mixer for 20 seconds.

The toluene layer was separated from

the aqueous phase by centrifugation in a clinical, desk-top centrifuge,
and 1.0 ml of the upper toluene phase was withdrawn, mixed with 10 ml
of Aquasol {NEN) scintillation cocktail and counted in a Packard
TRI-CARB liquid scintillation spectrometer.

N5-c~FH4 + E-FAD <
NADP+ <

NADPH + H+

> E-FADH2 + Ns.

a

I

1

'

I

I

N'° -CH2FH4

MENADIONE

> MENADIONE - H2

E-FAD
Fig. 6.

Reaction Utilized for the Assay of Methylene Tetrahydrofolate Reductase

I-'

CD
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Purification Procedure
Identical procedures were etnployed in the purification of

s 10
N 1 N •methylene tetrahydrofolate reductase from pig kidney and from
mouse Ll210-induced tumor tissue.

rresh pig kidney was obtained

"hot-off the hog", as it were, from a local slaughterhouse, frozen
inunediately in dry ice and kept at -40

0

c.

Mouse tumor tissue was

obtained by subcutaneously inoculating the flanks of laboratory mice
with a leukemic strain obtained from a host ascites tumor.

Seven days

following inoculation, the solid tumors (about l/2 g each) were
excised and stored at

-ao c.
0

The procedure for purification described

below is for a preparation of approximately 500 g of tissue.

All steps

in the purification were performed at 0-4°c, unless otherwise indicated.
1.

Extractions

500 g of tissue were partially thawed, and

homogenized with 1.2 liters of

o.os

M potassium phosphate buffer

(pH 7.2) in a Waring blendor for 3 minutes.

The crude homogenate was

filtered through several layers of cheesecloth, the filtrate adjusted
to pH 6.0 with 4 M acetic acid, and centrifuged in a sorvall RC2·B
refrigerated centrifuge at 27,000 x g for 30 minutes.
2.

Fractionation with (NH4)

so : Solid (NH4) 2so4 was added

2 4

with constant stirring to the supernatant to effect 25% saturation
(144 g (NH4 ) so /lfter of enzyme solution].
2 4

The ammonium sulfate•

protein solution was allowed to equilibrate with constant stirring for
15 minutes and then centrifuged at 27,000 x 9 for 35 minutes.
(NH4)

Solid

so4 was similarly added to the 25\ supernatant [125 g (NH4) 2

2

so4/liter of solution] to achieve 45% of saturation. 'l'his solution
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was stirred and centrifuged as before.

The resulting pellet

(representing a 25-45% cut) was homogenized in a Potter-Elvehjem glass
homogenizer, resuspended in cold distilled water and brought to a
total volume of 300 ml.
3.

Acid precipitation:

The resuspended ammonium sulfate

fraction was adjusted to pH 4.5 by the dropwise addition of 4 M acetic
acid and allowed to stir for 10 minutes, followed by centrifugation at
35,000 x g for 10 minutes.

The pellet was resuspended in 100 ml of

0.05 M potassium phosphate buffer (pH 7.2), pH adjusted to 7.2 with lM

NH 0H, and the preparation allowed to stand overnight.
4

The suspension

was then centrifuged at 35,000 x g for 15 minutes to yield a clear,
yellow supernatant.

The precipitate was discarded.

4. Acetone Fractionation:

Sufficient 1 M potassium phosphate

buffer (pH 7.2) was added to the clear, yellow supernatant to bring
the phosphate concentration to approximately 0.1 M, and the enzyme
solution was chilled in an. ice•salt mixture to 0°C.

One-half volume

of acetone (-25°C) was added rapidly with stirring and the turbid
solution was centrifuged (-15 C) at 35,000 x g for lo minutes.
0

The

supernatant was decanted into a pre-chilled beaker and an additional
one-half volume of acetone added rapidly with stirring, followed by
centrifugation C-15°C) at 35,000 x g for 10 minutes.

The supernatant

was discarded and the fairly solid, white pellet was thoroughly aspi•
rated, then resuspended in a minimum volume (about 40 ml) of 0. OS Mpotassium
phosphate buffer (pH 7.2).

The suspension was aspirated again, allowed

to stand for 60 minutes, and centrifuged at 35,000 x g for 15 minutes.
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The clear, yellow supernatant was carefully withdrawn and samples were
assayed for reductase activity.

As we found the acetone fractionation

to be less predictable than other steps in the purification procedure,
we deemed it wise to delay the combination of simultaneously run
preparations until the completion of the acetone step and verification
of reductase activity.

In the case of the pig kidney preparation, the

active fractions from four processings were combined at this stage of
purification.
5.

DEAE-cellulose chromatography:

A 3 cm x 25 cm column was

prepared from DEAE-cellulose DE-52 (Whatman) and equilibrated with

o.os

M potassium phosphate buffer (pH 7.2) until the affluent

tered a pH of 7.2.

regis~

The combined acetone fractions in the case of the

pig kidney preparation and a single preparation in the case of the
tumor tissue were loaded onto the column and washed with 2 liters of
o.15 M potassium phosphate buffer (pH 7.2).

The enzyme apparently had

a high affinity for the positively-charged matrix, as a
band was readily visible near the top of the column.

sharp, yellow

The protein was

then eluted from a linear ionic gradient of 250 ml each of 0.4 M and
0.6 M potassium phosphate buffer (pH 7.2) and collected in S ml
fractions at a flow rate of 60 ml/hour.

The protein was monitored

by

measuring the absorbance at 280 nm and assayed for reductase activity.
6.

DEAE-sephadex chromatography:

A shorter coluxnn (3 em x

12 cm) of DEAE-sephadex A-50 was prepared and equilibrated with 0.15 M
KCl.

The active fractions from the DE-52 column were combined and

diluted 1:3 with water to lower the ionic strength and pertnit

22
adsorption onto the column.

The adsorbed protein was washed with

2 liters of 0.2 M KCl and eluted from a linear ionic gradient of 300 ml
each of 0.4 M and

o.6 M KC!. The active fractions were

~onitored

and

assayed as described previously and the combined fractions were made
0.002 M in mercaptoethanol.
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Crude Kidney Homogenate

Discard

Ammonium Sulfate ( 0-25 %)
.Oc.0~

~,

Discord

Ammonium Sulfate ( 25·45 %)

Acid Precipitation (pH 4. 5 >

Discard

'°c.O/

~,

Acetone

!

Discord

DEAE-Cel Iulose

!

DEAE-Sephodex
Fig. 7. Flowchart of the Purification of Methylene
Tetrahydrofolate Reductase
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Results and Discussion
The results for the purification of methylene tetrahydtofolate
reductase from porcine kidney are summarized in Table I.

We would

estimate the enzyme to be of approximately equal purity with the
reported purification from rat liver (specific activity
min/mg protein) of Kutzbach and Stokstad (16).

= 109 runoles/

The higher fold purifi•

cation reported for our preparation reflects the difference in enzyme
levels in the two tissues.

While we do not attempt to report a degree

of purity, it would appear from the sharpness and symmetry of the column elution pattern (Figure 8) that there is a significant correlation
between reductase activity and protein levels, as also illustrated by
the superimposable protein and activity peaks.

The specific activity

remained relatively constant in all fractions.
The purification summary for methylene tetrahydrofolate reduc•
tase isolated from mouse Ll210-induced tumor tissue is displayed in
Table II.

As is evident, we chose to purify the tumor enzyme only

through the first ion exchange column.

It is interestinq to note that

the kidney enzyme and the tumor enzyme behaved identically throughout
the purification process, even to the extent of displaying similar
column elution profiles.

The similarity in the two enzymes was also

reflected in the constant ratio of specific activities at each stage
of purification.
The first three steps in our purification scheme were modified
from that of Kutzbach and Stokstad (16), the only major alteration
being in the ammonium sulfate fraction, where we found only negligible
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Table I
Purification of Methylene Tetrahydrofolate Reductase from Porcine Kidney

Crude Homogenate

483,000

63.,.000

0.1

100

Supernatant (pH 6.0)

109,000

55,900

0.5

89

5

28,560

45,100

1.6

72

16

Acid Precipitation (pH 4.5)

4,130

38.,.000

9.2

61

92

Acetone Fractionation

1.,092

15.,.000

13.5

24

135

150

8.,.800

58.3

14

583

20

2,120

105.0

3

1050

2

so4

(25-45%)

DEAE-Cellulose
DEAE-Sephadex

Specific Acitivty
(Units/mg)

Fold

Total Protein
(mgs)

(N11.4)

Total Activity
(Units)*

% Recovery

Purification Step

*expressed in mnoles/min

"'
0\

Table II
Purification of Methylene Tetrahydrofolate Reductase
from Mouse Ll210-Induced Tumor Tissue
Purification Step

Total Protein
(mgs)

Total Activity
(Units)*

Specific Activity
(Units/mg)

% Recovery

Crude Homogenate

20,400

816

0.04

100

3,065

613

0.20

75

5

840

496

0.59

61

15

164

336

2.05

41

51

23

142

6.24

17

156

8

124

15.48

15

387

Supernatant (pH 6.0}
(NH4)

2

so4 (25-45%)

Acid Precipitation (pH 4.5)
Acetone Fractionation
DEAE-Cellulose

Fold

*expressed in nmoles/min

"'...,,
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reductase activity in the 0-25% fraction.

Thus, we were able to

achieve a significantly higher degree of purification by retaining the
more active 25-45% cut.

Some attempts have been made, both in this

laboratory (26) and elsewhere (17); at using a protamine sulfate step'
prior to ammonium sulfate fractionation.

While a reasonably good fold

purification was achieved, we rejected this method as being too costly
in tenns of loss of total activity.
The acetone step was, to my knowledge, the first reported use
of precipitation by organic solvents in the purification of methylene
tetrahydrofolate reductase from mammalian tissue.

Considerable effort

was expended in the optimization of conditions for this differential
solvent precipitation, particularly in correlating the phosphate concentration with the volume of acetone to be added for maximum reduc•
tase yield.

Care also needed to be exercised in lowering the tempera-

ture of the enzyme solution to minimize loss of enzyme activity as a
result of freezing and adherence to the walls of the reaction vessel.
Despite the difficulties involved in standardizing this step, although
it accounted for only a two-fold increase in specific

activity above

the previous step, it succeeded in solving two problems which had
plagued earlier investigators:

l) it lowered the protein concentration

sufficiently as to facilitate subsequent chromatographic purification1
and 2) it purified the reductase fraction of contaminating methionine
synthetase and serine transhydroxymethylase activities, a significant
prerequisite for the kinetic and inhibition studies which will be
discussed in the next chapter.
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It was determined by initial batch elution studies that at
neutral pH methylene tetrahydrofolate reductase was bourid tightly to
the diethylaminoethyl group.

We found that a column of DEAE•cellulose

DE-52 would concentrate both the kidney and tumor enzymes into a single
band near the top of the column, detectable due to the
flavin prosthetic group.

tightly-~ound

Several protein contaminants appeared to be

removed by the wash with buffer of low ionic strength and the active
enzyme was eluted in a single, relatively narrow peak by the increasing
ionic gradient.

As previously mentioned, both enzymes were eluted with

an approximately equal volume and ionic strength of potassium phosphate
buffer.
DEAE-sephadex A-SO chromatography was an attempt to combine
the property of ion exchange associated with the diethylaminoethyl
functional group with the molecular sieve of the sephadex beads.

While

this step did result in a two-fold purification above the DEAE•cellU•
lose fractions, we anticipate that the enzyme will be purified to a
greater degree of homogeneity by affinity chromatography (27•30).
Some additional

obser~ations

pertaining to the purified methy•

lene tetrahydrofolate reductase are appropriate at this point 1n the
discussion.

It is evident that, in the sequence of purification, the

enzyme has retained a considerable amount of its initial activity des•
pite relatively drastic procedures, such as the acid precipitation at
pH 4.5 and the acetone fractionation.

This would appear to indicate

that the flavin moiety associated with the enzyme is tightly bound to
the apoenzyme.

An "Achilles heel" on the otherwise extremely stable

enzyme appears to be a free sulfhydryl group associated with the
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catalytic activity.

The purified reductase was observed to lose

activity rapidly with refrigeration1 however, the enzyme retained
approximately 95% activity after storage for one month at 0-4°C when
made 0.002 M in mercaptoethanol; a reagent connnonly utilized to prevent
air oxidation of sulfhydryl groups.

Supporting evidence for this hypo-

thesis is provided in the report of almost complete inhibition of reductase activity by p-hydroxymercuribenzoate (17), an enzyme inhibitor
which is postulated to react with free sulfhydryl groups.

ENZYME CHARACTERIZATION

Kinetic Properties
5

The kinetics of N ,N
from both kidney

and

10

methylene tetrahydrofolate reduotase

tumor tissue have been studied.

Both enzymes ex•

hibit characteristic Michaelis-Menten saturation kinetics with respect
to the reverse assay technique employed, using menadione as the
electron acceptor and [C
substrate.

14

5
J-N -methyl tetrahydrofolate as the variable

The linear Lineweaver-Burk double reciprocal plots were

utilized as a criterion for determination of the maxisnum velocity
) and the Michaelis constant (l<m), as well as for the claesifica•
max
tion of the types of inhibition (31·33). The type of inhibition has
(V

been classified according to Cleland (32) :

competiti~e

inhibition

alters the slope of the double reciprocal plot without affecting the
intercept1 non-competitive inhibition alters both the slope and the
intercept, with a resultant convergence point to the left of the
ordinate axis.

Competition is defined to be linear when replot of the

slope vs. inhibitor concentration yields a straight line.

on the basis

of these kinetics data, we have reported that the kidney enzyme ex•
hibits a

of 2.0 x 10

-4

M and a V
of 67 nmoles/min/mg protein;
max
-4
whereas the tumor enzyme has a Km of 2. 4 x 10 M and a V
of
max
Km

29 nmoles/min/mg portein.

Thus, to the extent that each enzyme has

been purified, it would appear that the "normal" enzyme has a slightly
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Fig. 9. Saturation of Kidney Methylene Tetrahydrofolate
Reductase by NS-methyl Tetrahydrofolate
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greater affinity for Ns-methyl tetrahydrofolate and a considerably
higher maximum velocity.

Exactly what the physiological significance

of this observation might be cannot readily be determined until

a

more

extensive investigation of the regulatory controls involved in
one-carbon metabolism is attempted.
The Hill plot (31), a kinetic tool for determination of the
number of interacting substrate sites per molecule of enzyme, is linear
for both enzymes and yields an "n" value of l.

Both enzymes exhibit

fairly broad pH optima for assay in the reverse direction with an
optimum velocity at pH 6.3 for the kidney enzyme and a slightly more
acidic pH optimum of 6.1 for the tumor enzyme.
Inhibition Studies
overview
As mentioned in the introductory chapter, a primary justifica•
tion for this research effort was the screening of a nwnber of natural
and synthetic compounds for methylene tetrahydrofolate reductase inhi•
bition.

By consolidating data regarding the biochemistry and toxicol•

ogy of such potential chemotherapeutic drugs, the National Cancer
Institute hopes to eliminate the trivial compounds so that available
resources can be more judiciously applied to the clinical trial of a
few promising anti-cancer agents.

To this end, we have investigated a

number of compounds: some furnished by the National Cancer Institute,
others by cooperating laboratories, still others that we have synthesized in our laboratory.

These potential chemotherapeutic dru9s,

generally either alkylating agents or antifolates, have been routinely
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screened at various concentrations for inhibition of methylene tetrahydrofolate reductase activity by the previously described artificial
assay technique.

The inhibitor constant (Ki) for each of these com•

pounds was determined by the method of Dixon (31).
5

Synthesis of N -Alkyl Tetrahydrofolate
and NS-Alkyl Tetrahydrohomofolate
Derivatives
5
For the purpose of analyzing the effect of the higher N -alkyl
5

homologs of N -methyl tetrahydrofolate on methylene tetrahydrofolate
reductase activity, as well as other enzymes involved in folatedependent, one-carbon metabolism, we have synthesized the following
5

5

compounds: N -ethyl tetrahydrofolate, N -propyl tetrahydrofolate,
5
5
14
5
N -butyl tetrahydrofolate, N -methyl tetrahydrohomofolate, (C )•N •
methyl tetrahydrofolate, [C

14

s

]-N -ethyl tetrahydrofolate, and (C

5

N -ethyl tetrahydrohomofolate.

14

]•

Both tetrahydrofolate and tetrahydro•

homofolate were routinely prepared by the platinum oxide catalyzed
reduction of folate (homofolate) in glacial acetic acid under hydrogen
gas pressure according to the method of O'dell (19) as modified by
Hatefi (20).

5

The N -alkyl analogs were then formed by the addition of

5 10
the appropriate aldehyde, yielding the N ,N -bridged condensation

product, which was subsequently reduced by KBH

4

(21) and purified from

folate contaminants by ion exchange chromatography, as previously des•
cribed in the methods section.
mined spectrophotometrically.
Figure 12.

The purity of the product was deter•
Typical spectra are illustrated in
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Inhibition of Kidney Reductase by
NS-Alkyl Tetrahydrofolate
Derivatives

.

s

Studies of inhibition of the kidney enzyme by N •ethyl tetra•
5

5

hydrofolate, N -propyl tetrahydrofolate and N •butyl tetrahydrofo1ate
have indicated that these comPe>unds are competitive inhibitors.

Xi

-4
•4
values have been determined to be 6.0 x 10 M, 4.0 x 10 M and
2.3 x 10-4 M, respectively, with replots of these data illustratin9
linear competition.

We had anticipated, based on the relative steric

hindrance of the higher homologs, that the order of inhibition would
be:

5

5

5

N •ethyl > N -propyl > N •butyl tetrahydrofolate.

As the sequence

of these compounds was reversed from what we had predicted• we postu•
lated that the effective inhibitor concentration was diminishing
during the course of reaction, the most likely explanation being a
turnover of labile ethyl groups with a reduced turnover rate in the
higher homologs.

Preliminary results indicated that methylene tetra•

hydrofolate reductase will catalyze the oxidation of [C14 ]-Ns•ethyl
14
tetrahydrofolate to the tc 1-N5 ,N10-ethylidene tetrahydrofolate
adduct1 however, further studies will be required to confirm this
observation.

5

N -methyl tetrahydrohomofolate was shown to inhibit the

kidney reductase non-competitively (Ki• 1.7 x 10-4 M) and preliminary
14
5
studies with cc J-N -methyl tetrahydrohomofolate have shown no
evidence of turnover.
Reductase Inhibition by Alkylating
Agents
The alkylating agents examined for reductase inhibition were
solely those of the Baker antifolate variety.

These compounds,

Table III
5
Inhibition of Methylene Tetrahydrofolate Reductase by N -Alkyl Tetrahydrofolate
and NS-Alkyl Tetrahydrohomofolate Derivatives
Compound
5

N -ethyl tetrahydrofolate
5

N -propyl tetrahydrofolate
5

N -butyl tetrahydrofolate
5

N -methyl tetrahydrohomofolate

Type of Inhibition

Slope Replot

K.].

-

Competitive

Linear

-4
6.0 x 10
M

Competitive

Linear

-4
4.0 x 10
M

Competitive

Linear

-4
2.3 x 10
M

---

-4
1.7 x 10
M

Non-competitive
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structurally similar to natural folate substrates, contain a sulfonyl
fluoride functional group, which is presumed to alkylate the enzyme at
a locus which would inhibit enzyme activity.

Preliminary screening

studies with Baker antifolates showed them to inhibit reductase activity only negligibly at physiologically significant concentrations.

Upon

the suggestion that our pre-incubation time of five minutes might be
insufficient to permit the alkylation reaction, time course assays were
performed with pre-incubation times of 5, 20, 35, 65, and 125 minutes.
While this type of assay revealed some valuable information regarding
the inhibition of another enzyme currently being studied in this
laboratory, serine transhydroxymethylase, the time of pre-incubation
had no significant effect on methylene tetrahydrofolate reductase inhibition by Baker antifolates.
Reductase Inhibition by Folate Analogs
K. values were determined for reductase inhibition by seven
1

folate analogs.

The results for the inhibition of the kidney and

tumor enzymes are summarized in Table IV.
Time course screens were performed on each of the above compounds with pre-incubation times of 5 minutes and 125 minutes, with no
significant change in the degree of enzyme inhibition.

A general ob-

servation is that the tumor enzyme appears more resistant to inhibition
by folate analogs than the kidney enzyme.

Whether this is of any

physiological significance or merely a function of the difference in
enzyme sources can only be determined by the comparison of normal
tissue with a less artificial cancer model.

Of significance is the
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observation that, under the condition of this assay, methotrexate, a
drug used clinically in the treatment of a number of solid and systemic
cancers, appears to be less effective at inhibiting methylene tetra•
hydrofolate reductase activity than several other folate compounds.
This is particularly apparent with the kidney enzyme, where aminopterin
and leukovorin exhibit approximately 10-fold higher inhibition and the
2',5'-dichloro-dcrivative of methotrexate improves the inhibition by
100-f.old relative to the methotrexate standard.

Since these compounds

may not inhibit dihydrofolate reduetase as effectively as methotrexate,
should they be determined to have an inhibitory effect on other folate
dependent enzymes, such as methionine synthetase or serine transhydroxymethylase, it would suggest their possible implementation in
clinical trials in combination therapy with methotrexate to maintain
remission even with elevated levels of dihydrofolate reduetase.
Another application of these antifolate compounds, if not as
pleasing to one's humanitarian senses, at least more practically
imminent, is its possible utilization in affinity chromatography for
further enzyme purification.

Similar compounds are readily

covalently-linked to a cyanogen bromide activated carbohydrate (e.9.
agarose) support medium, and this technique is currently under
investigation in this laboratory.

Table IV
K. Values of Selected Inhibitors of Methylene Tetrahydrofolate Reductase
1

Type of Inhibition

Kidney Enzyme

Tumor Enzyme

Methotrexate

Non-Competitive

-4
2.3 x 10
M

-4
5.4 x 10
M

Aminopterin

Non-Competitive

-5
1.8 x 10
M

-4
3.4 x 10
M

Dichloromethotrexate

Non-Competitive

3.8 x 10

Leukovorin

Non-Competitive

1. 7 x 10

Homofolate

Non-Competitive

Not determined

5.1 x 10

Tetrahydrofolate

Non-Competitive

-4
1.6 x 10
M

-4
2.3 x 10
M

Non-Competitive

-4
1.7 x 10
M

-4
1.9 x 10
M

Compound

5

N -methyl Tetrahydrohomofolate

-6

-5

-5

M

8.2 x 10

M
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SUMMARY

Methylene tetrahydrofolate reductase has been partially purified 1000-fold from porcine kidney and 400-fold from mouse Ll210induced tumor tissue by similar procedures.

While.the two enzymes

behaved similarly throughout purification, kinetic characterization
and inhibition studies have revealed subtle differences between the
"normal" and tumor enzymes which, upon further investigation, miqht
prove valuable in the specific inhibition of malignancy.

These differ-

ences include a slight variation in pH-activity profile, general enzyme
stability in the purified state, substrate affinity, and resistance
to enzyme inhibition by folate analogs.
Several compounds have been demonstrated to inhibit methylene
tetrahydrofolate reductase activity at physiological levels, which
suqgests their possible implementation, pending the outcome of

toxi~

cology trials, in cancer chemotherapy in combination with methotrexate.
It is anticipated that, through the use of these inhibitors in affinity
chromatography, methylene tetrahydrofolate reductase will shortly
purified to a greater degree of homogeneity.

46

be

LIST OF REFERENCES
1.

Carter, s. 1<.. and Slavik, M. "Chemotherapy of Cancer," in Annual
Review of Pharmacology, Vol. 14, H. w. Elliott, ed. Palo Altot
Annual Reviews, Inc., 1974.

2.

Bodey, G. P. and Frei, E., III. "Medical Therapy of Cancer,•• in
Principles of Internal Medicine, 7th ed. T. R. Harrisont ed.
New York: McGraw-Hill Book co., 1974.

3.

Friedkin, M.

4.

Farber, S.1 Diamond, L. K.r and Mercer, R. D.
238: 787 (1948).

5.

Frei, E., III; Jaffe, N.1 Tattersall, H. N.1 Pitman, S.; and
Parker, L. N. England J. Med., ~1 846 (1975).

6.

Donaldson, K.

7.

Donaldson, K. o. and Keresztesy, J.
3235 (1959).

a.

Donaldson, K. o. and Keresztesy, J. c.
1298 (1962).

9.

Donaldson, K.

10.

Donaldson, K.

11.

Larrabee, A. R. and Buchanan, J. M.

12.

Cathou, R. E. and Buchanan, J. M.

comm.,

i=

Adv. Enzymol., 38: 235 (1973).

N. England J. Med.,

-

o. and Keresztesy, J. c. Fed. Proc., 18:

o. and Keresztesy, J.
289 (1961).

o. and

Keresztesy, J.

c. J. Biol. Chem.,

216 (1959).

234&

J. Biol. Chem., 2371

c. Biochem. Bioihys. Res.

c.

-

Fed. Proc., 20t 453(1961).

Fed. Proc.,

~t

9 (1961).

13.

Hatch, F. T.1 Takayama, s.1 Cathou, R. E.1 Larrabee, A. R.J and

14.

Kisliuk, R. L.

15.

Katzen, H. M. and Buchanan, J. M.

16.

Kutzbach, c. and Stokstad, E. L. R.
250: 459 (1971).

Buchanan, J.M.

J. Biol. Chem., 238: 1746(1963).

J. Am. Chem. Soc., 81: 6525 (1959).

J. Biol. Chem., 238: 397 (1963).

47

J. Biol. Chern., ~· 825 (1965).

Biochim. Biophys. Acta,

48

17.

Gi9liotti, H. J. and Huenneken1,
1968.

18.

Broderick, D.
!• 207 (1972)

19.

s.,

r.

M.

Unpubli1hed Manu1cript,

North, J. A.1 and Man;um, J. H.

Pree. Biochem.,

I

O'Dell, B. L.1 Vandenbelt, J. M.1 Bloom,
J. Am. Chem. Soc.,§!• 250 (1947).

s. s.,

and Pfiffner, J. J.

20.

Hatefi, Y.1 Talbert, P. 'l'.1 Osborn, J. J.1 and Huennekene, r. M.
in Biochemical Preparations, Vol. 7, H. A. Lardy, ed. New
Yorks Wiley, 1960.

21.

Blair, J. A. and Saunders, K. J,

22.

Xereazteay, J. c. and Donaldson, K.
Comm., .§..: 286 (1960).

23.

Gornall, A. G.1 Baradawill,
Chem., .!!11 751 (1949).

24.

Lowry, o. H.1 Rosebrough, N. J.1 Farr, A. L.1 and Randall,
J. Biol. Chem., !21= 265 (i9Sl).

25.

Ross, E. and Schatz, G.

26.

Hadfield, K. L.

27.

Mell, G. P.1 Whiteley, J. M.1 and Huennekens, F. M.
Chem., fila 6074 (1968).

28.

Poe, M.1 Greenfield, N. J.1 Hirschfield, J. M1 Williams, M. N.1
and Hoogsteen, K. Biochemistry, lla 1023 (1972)~

29.

Whiteley, J. M.1 Mell, G. P.1 and Huennekens, F. M.
Biophys., ~: 15 (1972).

30.

Kaufman, B. 'l'. and Pierce, J, V.
~· 608 (1971).

31.

Dixon, J. and Webb, E.
1964.

32.

Cleland, w. w. "Steady state Kinetics," in The Enz)'!llea, 3rd ed.,
P. D. Boyer, ed. New York: Academic Press, 1970.

33.

Plowman, K. M.
1972.

c.

-

Anal. Biochem., 4lt 332 (1971).

o.

Biochem. Biophya. Rea.

J.1 and David, M. M.

Anal. Biochem.,

~·

J. Biol.

a. J.

304 (1973).

Unpublished results, 1975.

c.

J. Biol.

Arch. Biochem.

Biochem. BiophfS• Res. Comm.,

Enzymes, 2nd ed.

London& Longmans,

Enzyme Kinetics. New York: McGraw-Hill Book co.,

5
S'l'UDIES OF N ,N10-METHYLENE TETRAHYOROFOLATE R.EOUCTASE FROM
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ABSTRACT
Methylene tetrahydrofolate reductase has been purified
1000-fold from porcine kidney and 400-fold from mouse Ll210-induced
tumor tissue by classical methods. The enzyme preparations have been
dell\Onstrated to be essentially free of contaminating methionine syn•
thetase and serine transhydroxymethylase activity.
Studies of the kinetic properties of the kidney and tumor
enaymea, with respect to the reverse reaction using NS-methyl tetrahydrofolate as the variable substrate, have indicated Km values of 2.0
and 2.4 x io-4 M, respectively. Inhibition of this key branch point
enzyme in folate metabolism by a number of antimetabolites indicates
that several of these antifolate compounds exhibit enzyme inhibition
superior to that of methotrexate, a druq extensively utilized in the
maintenance of remission in cancer chemotherapy.
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